The FDA approved Roche’s cobas HPV test for first-line screening of cervical cancer in women 25 and older using cervical specimens collected in SurePath preservative fluid, commonly used in Pap tests.

New process allows labs to use same Pap test vial instead of transferring sample to new vial, thus simplifying workflow INDIANAPOLIS, June 26, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) ...

Pelvic exams are no one’s idea of fun. No matter how many you’ve done, no matter how prepared you are, that moment when the ice cold speculum wrenches open your vagina never gets more comfortable. As ...

The Health Resources and Services Administration just released new guidelines for cervical cancer screenings, which include ...

Basel, 16 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of a human papillomavirus (HPV) self sampling solution in countries accepting the CE mark. This new solution enables ...

Introduction Self-sampling for cervical cancer screening is a promising strategy to improve coverage and reduce strain on ...

The Roche cobas HPV Test has been approved by the FDA. A new HPV screening test that uses cervical cells collected for a Pap test has been approved by the FDA. The FDA has approved the Roche cobas HPV ...

A test that can detect the DNA of the human papilloma virus (HPV), to confirm the need for cervical cancer screening in women 25 years and older, has gained the FDA’s support as a primary screening ...

The U.S. Food and Drug Administration (FDA) has approved a human papillomavirus (HPV) DNA test for women 25 and older that can be used to determine whether these women should have additional ...

(RTTNews) - Biopharmaceutical company Roche Holding AG (RHHBY), announced on Tuesday that its cobas HPV test for use on the cobas 6800/8800 Systems has been awarded the World Health Organization (WHO) ...